Application of Autologous Stem Cells From Adipose Tissue in the Regeneration of Knee Joint Cartilage
Key facts
- Who runs it
- Clinical Center of Vojvodina
- Where
- Serbia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 60 people enrolled
- Started
- 25 Jun 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- stromal vascular fraction (SVF)
- CP
- Record updated
- 12 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Adults (≥18 years)
- Radiologically confirmed knee OA (grades II-IV, Kellgren-Lawrence scale)
- KOOS pain score ≤ 60 points
- Symptomatic degenerative knee disease with at least 6 months of persistent pain
- No history of major knee trauma or prolonged immobilization (>10 days)
Who cannot take part
- Current anticoagulant or antiplatelet therapy
- Intra-articular corticosteroid injection within the past 6 months
- History of major knee trauma or surgery
- Minors (<18 years)
- Asymptomatic OA (KL grade 0-I)
- Severe axial deformity (varus >10°, valgus >10°)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized, controlled clinical trial will evaluate the safety and effectiveness of autologous adipose-derived stromal vascular fraction (SVF) therapy in patients with knee osteoarthritis (OA) grades II-IV, compared with standard chondroprotective (CP) treatment. The study will enroll male and female patients and follow them for 12 months, assessing pain (VAS), function (WOMAC, KOOS, SF-36), radiologic progression, and safety (adverse events). The trial aims to determine whether SVF therapy provides superior clinical outcomes and to inform evidence-based recommendations for OA management in the Serbian population.
The 2 groups in the trial
- SVF groupTreatment being tested
In this arm, we included patients which will be treated with intraarticular injection of SVF from fat pad
Treatment: stromal vascular fraction (SVF)
- CP groupExisting treatment, for comparison
In this arm we will included patient swhich will be treated with Reviscon Re cross HA injection by MV Pharm
Treatment: CP
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 12 February 2026